EyePoint Pharmaceuticals announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a specific and permanent reimbursement J-code through the Healthcare Common Procedure Coding System (HCPCS) for Dexycu (dexamethasone intraocular suspension) 9%. Dexycu is the first and only FDA-approved, single dose, sustained-release, intracameral steroid for the treatment of postoperative inflammation.
“The issuance of a specific and permanent J-code for Dexycu is another key milestone for the company that allows for a convenient and simplified reimbursement process that is familiar to administering physicians and the greater insurance community,” Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals, said in a company news release. “The addition of a permanent and specific J-code is also important to our commercial strategy as such codes are utilized by CMS and commercial insurers enabling us to address the entire population of patients requiring postoperative ocular inflammation treatment in the U.S. We continue to expect to commercially launch Dexycu in the U.S. in the first half of calendar 2019 following the completion of a successful commercial supply scale-up.”
The code, J1095, will become effective on January 1, 2019, and will replace the previously issued C-code for Dexycu (C9034) that became effective on October 1, 2018. The company still retains transitional pass-through status for Dexycu from CMS for approximately 3 years.